Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2017, Article ID 6868030, 11 pages
https://doi.org/10.1155/2017/6868030
Research Article

Results of a Qualitative Study to Develop a Patient Reported Outcome Measure for Patients with 4 Subtypes of Soft Tissue Sarcoma

1Evidera, Seattle, WA, USA
2Novartis Oncology, East Hanover, NJ, USA
3Evidera, Bethesda, MD, USA

Correspondence should be addressed to Anne M. Skalicky; moc.aredive@ykcilaks.enna

Received 29 November 2016; Revised 3 March 2017; Accepted 14 March 2017; Published 14 May 2017

Academic Editor: Peter C. Ferguson

Copyright © 2017 Anne M. Skalicky et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Chen, R. Borker, J. Ewing et al., “Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology network,” Sarcoma, vol. 2014, Article ID 145764, 7 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. J. R. Toro, L. B. Travis, J. W. Hongyu, K. Zhu, C. D. M. Fletcher, and S. S. Devesa, “Incidence patterns of soft tissue sarcomas, regardless of primary site, in the Surveillance, Epidemiology and End Results program, 1978–2001: an analysis of 26,758 cases,” International Journal of Cancer, vol. 119, no. 12, pp. 2922–2930, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Gustafson, H. Willen, B. Baldetorp, M. Ferno, M. Akerman, and A. Rydholm, “Soft tissue leiomyosarcoma: a population-based epidemiologic and prognostic study of 48 patients, including cellular DNA content,” Cancer, vol. 70, no. 1, pp. 114–119, 1992. View at Publisher · View at Google Scholar · View at Scopus
  4. National Comprehensive Cancer Network (NCCN), Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma, 2015.
  5. S. L. Shingler, P. Swinburn, A. Lloyd et al., “Elicitation of health state utilities in soft tissue sarcoma,” Quality of Life Research, vol. 22, no. 7, pp. 1697–1706, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Colosia, S. Khan, M. D. Hackshaw, A. Oglesby, J. A. Kaye, and J. M. Skolnik, “A systematic literature review of adverse events associated with systemic treatments used in advanced soft tissue sarcoma,” Sarcoma, vol. 2016, Article ID 3597609, 13 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Saponara, S. Stacchiotti, and A. Gronchi, “The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma,” Expert Review of Anticancer Therapy, vol. 16, no. 5, pp. 473–484, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. Food and Drug Administration, Guidance for industry on Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, Division of Drug Oncology Products and the Division of Biologic Oncology Products in the Center for Drug Evaluation and Research (CDER), 2007.
  9. Food and Drug Administration, “Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims,” Federal Register, vol. 74, no. 235, pp. 65132-65133, 2009. View at Google Scholar
  10. E. Basch, B. B. Reeve, S. A. Mitchell, and et al., “Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE),” Journal of the National Cancer Institute, vol. 106, no. 9, 2014. View at Google Scholar
  11. D. L. Patrick, L. B. Burke, C. J. Gwaltney et al., “Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1—eliciting concepts for a new PRO instrument,” Value in Health, vol. 14, no. 8, pp. 967–977, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. D. L. Patrick, L. B. Burke, C. J. Gwaltney et al., “Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 2—assessing respondent understanding,” Value in Health, vol. 14, no. 8, pp. 978–988, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Rothman, L. Burke, P. Erickson, N. K. Leidy, D. L. Patrick, and C. D. Petrie, “Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR good research practices for evaluating and documenting content validity for the use of existing instruments and their modification PRO task force report,” Value in Health, vol. 12, no. 8, pp. 1075–1083, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. A. M. Skalicky, S. R. Ghate, J. R. Perez, and A. Rentz, “Developing a Patient-Reported Outcome Measure for Patients with 4 Subtypes of Soft Tissue Sarcoma,” Value in Health, vol. 19, no. 3, article A96, 2016. View at Publisher · View at Google Scholar
  15. N. K. Aaronson, S. Ahmedzai, B. Bergman et al., “The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology,” Journal of the National Cancer Institute, vol. 85, no. 5, pp. 365–376, 1993. View at Publisher · View at Google Scholar · View at Scopus
  16. C. S. Cleeland, T. R. Mendoza, X. S. Wang et al., “Assessing symptom distress in cancer patients: the M. D. Anderson Symptom Inventory,” Cancer, vol. 89, no. 7, pp. 1634–1646, 2000. View at Google Scholar · View at Scopus
  17. L. A. Williams, D. M. Araujo, Q. Shi et al., “Symptoms in gastrointestinal stromal tumors,” in Proceedings of the 2014 ASCO Annual Meeting, Chicago, Ill, USA, 2014.
  18. J. E. Ware and C. D. Sherbourne, “The MOS 36-item short-form health survey (Sf-36): I. Conceptual framework and item selection,” Medical Care, vol. 30, no. 6, pp. 473–483, 1992. View at Publisher · View at Google Scholar · View at Scopus
  19. A. M. Davis, J. G. Wright, J. I. Williams, C. Bombardier, A. Griffin, and R. S. Bell, “Development of a measure of physical function for patients with bone and soft tissue sarcoma,” Quality of Life Research, vol. 5, no. 5, pp. 508–516, 1996. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Reichardt, M. Leahy, X. Garcia Del Muro et al., “Quality of life and utility in patients with metastatic soft tissue and bone sarcoma: the sarcoma treatment and burden of illness in North America and Europe (SABINE) study,” Sarcoma, vol. 2012, Article ID 740279, 11 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. S. P. Chawla, J. Blay, I. L. Ray-Coquard et al., “Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT),” Journal of Clinical Oncology, vol. 29, Article ID 10005, 2011. View at Publisher · View at Google Scholar
  22. V. Gupta, K. Gu, Z. Chen, W. Lu, X. O. Shu, and Y. Zheng, “Concordance of self-reported and medical chart information on cancer diagnosis and treatment,” BMC Medical Research Methodology, vol. 11, article 72, 2011. View at Publisher · View at Google Scholar · View at Scopus